TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05122481

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Vitamin C (also known as ascorbic acid and ascorbate) is a vitamin found in various foods and sold as a dietary supplement.Vitamin C is a water-soluble vitamin, with dietary excesses not absorbed, and excesses in the blood rapidly excreted in the urine, so it exhibits remarkably low acute toxicity. More than one gram may cause indigestion, flatulence and stomach pain.
Study: NCT05523726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pCBT-I
Description: Telehealth coaching
Study: NCT06227169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JJ-COPES Training
Description: • The JJ-COPES training is derived from an empirically supported CBT manual designed for outpatient treatment of suicidal adolescents. JJ-COPES training focuses on teaching 4 primary treatment strategies plus a caregiver session to community-based clinicians.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JJ-COPES Training
Description: • The JJ-COPES training is derived from an empirically supported CBT manual designed for outpatient treatment of suicidal adolescents. JJ-COPES training focuses on teaching 4 primary treatment strategies plus a caregiver session to community-based clinicians.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JJ-COPES Training
Description: • The JJ-COPES training is derived from an empirically supported CBT manual designed for outpatient treatment of suicidal adolescents. JJ-COPES training focuses on teaching 4 primary treatment strategies plus a caregiver session to community-based clinicians.
Study: NCT04753034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TER-101
Description: Active Comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Placebo Comparator
Study: NCT04763720

Intervention type: BEHAVIORAL
Intervention: Dyadic Developmental Psychotherapy
Description: DDP involves approximately twenty sessions with the family, conducted by a trained DDP therapist. DDP is developed to treat trauma-related and attachment difficulties. DDP is not a manualized treatment but involves using a set of core communication techniques (termed PACE; Playfulness, Acceptance, Curiosity and Empathy).
Study: NCT06458348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Local opera appreciating and Medical gymnastics training
Description: To construct a local opera viewing combined medical gymnastics training program for elderly patients with post-stroke cognitive impairment, and to explore its feasibility, acceptability and safety.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Local opera appreciating and Medical gymnastics training
Description: To construct a local opera viewing combined medical gymnastics training program for elderly patients with post-stroke cognitive impairment, and to explore its feasibility, acceptability and safety.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Local opera appreciating and Medical gymnastics training
Description: To construct a local opera viewing combined medical gymnastics training program for elderly patients with post-stroke cognitive impairment, and to explore its feasibility, acceptability and safety.
Study: NCT06427421

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Frequency of Treg and Teffs
Description: additionnal blood sampling at inclusion

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Frequency of Treg and Teffs
Description: additionnal blood sampling at inclusion

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Phenotype of Treg and Teffs
Description: additionnal blood sampling at inclusion

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Phenotype of Treg and Teffs
Description: additionnal blood sampling at inclusion

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: RNA seq analysis
Description: additionnal blood sampling at inclusion

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: RNA seq analysis
Description: additionnal blood sampling at inclusion

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: HLA typing
Description: additionnal blood sampling at inclusion

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: HLA typing
Description: additionnal blood sampling at inclusion

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: beta-cell autoantibody dosage
Description: additionnal blood sampling at inclusion

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: beta-cell autoantibody dosage
Description: additionnal blood sampling at inclusion

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Glycated haemoglobin (HbA1C) dosage
Description: additionnal blood sampling at inclusion

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood glucose dosage
Description: additionnal blood sampling at inclusion

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: C-peptide dosage
Description: additionnal blood sampling at inclusion
Study: NCT05673031

Intervention type: DIAGNOSTIC_TEST
Intervention: 68Ga-HA-DOTATATE PET/CT imaging
Description: Each patient will receive an IV injection 68Ga-HA-DOTATATE. Imaging will be conducted beginning 45-90 minutes after an injection of between 100-250 MBq 68Ga-HA-DOTATATE in patients.~* After the 68Ga-HA-DOTATATE acquisition is complete, a CT scan will be performed for attenuation correction and localization in the same in line gantry without patient movement between the two scans.~* The results of the 68Ga-HA-DOTATATE PET/CT will be compared to any prior imaging and pathologic results.
Study: NCT05907525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: To induce anesthesia, remimazolam is continuously infused in a dose of 6mg/kg/hr with remifentanil (Ce of 1-4ng/ml) by target-controlled infusion (TCI). Maintenance dose of remimazolam is 1mg/kg/hr, up to 2mg/kg/hr, and remifentanil is titrated to maintain the bispectral index (BIS) between 40 and 60 to achieve appropriate anesthetic depth during general anesthesia.~Inspired oxygen fraction (FiO2) 1.0 is used during mask ventilation and tracheal intubation. During two lung ventilation (TLV), tidal volumes (8mL/kg predicted body weight), positive end-expiratory pressure (PEEP) 5cmH2O with FiO2 0.3 is applied. At the start of one lung ventilation(OLV), tidal volumes (5mL/kg predicted body weight), PEEP 5cmH2O with FiO2 0.8 is applied. Intraoperative ventilatory frequency is 12 breaths/min, subsequently adjusted to maintain end tidal CO2(ETCO2) ranged between 35-40mmHg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% propofol
Description: To induce anesthesia, 1% propofol 1.5-2.5mg/kg is used with remifentanil (Ce of 1-4ng/ml) by target-controlled infusion (TCI). After patient loses consciousness, anesthesia is maintained through the inhalation of sevoflurane between 1-2 minimum alveolar concentrations (MAC), and remifentanil is titrated to maintain the bispectral index (BIS) between 40 and 60 to achieve appropriate anesthetic depth during general anesthesia.~Inspired oxygen fraction (FiO2) 1.0 is used during mask ventilation and tracheal intubation. During two lung ventilation (TLV), tidal volumes (8mL/kg predicted body weight), positive end-expiratory pressure (PEEP) 5cmH2O with FiO2 0.3 is applied. At the start of one lung ventilation(OLV), tidal volumes (5mL/kg predicted body weight), PEEP 5cmH2O with FiO2 0.8 is applied. Intraoperative ventilatory frequency is 12 breaths/min, subsequently adjusted to maintain end tidal CO2(ETCO2) ranged between 35-40mmHg.
Study: NCT04886414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone-based monitoring
Description: Study staff will perform daily phone-based assessments using standardized electronic study tools (tablets). Clinical features will be documented on a phone-based patient monitoring form.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone-based monitoring
Description: Study staff will perform daily phone-based assessments using standardized electronic study tools (tablets). Clinical features will be documented on a phone-based patient monitoring form.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone-based monitoring
Description: Study staff will perform daily phone-based assessments using standardized electronic study tools (tablets). Clinical features will be documented on a phone-based patient monitoring form.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone-based monitoring
Description: Study staff will perform daily phone-based assessments using standardized electronic study tools (tablets). Clinical features will be documented on a phone-based patient monitoring form.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen saturation monitoring
Description: Oxygen saturation will be monitored and recorded at regular intervals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen saturation monitoring
Description: Oxygen saturation will be monitored and recorded at regular intervals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol-based hand sanitizer
Description: Alcohol-based hand sanitizer will be distributed to subjects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol-based hand sanitizer
Description: Alcohol-based hand sanitizer will be distributed to subjects.
Study: NCT04733924

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aqueous extract of roots plus leaves of Withania somnifera 125 mg
Description: One capsule before breakfast for 84 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aqueous extract of roots plus leaves of Withania somnifera 250 mg
Description: One capsule before breakfast for 84 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline Cellulose
Description: One capsule before breakfast for 84 days
Study: NCT05560334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib Pill
Description: 13.5mg, po, 2 weeks on/1 week off, Q3W
Study: NCT05474495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Description: Pelvic floor muscle training. Two sessions a week for 6 weeks, each session lasting 45 mins.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transverse abdominas strength training
Description: Transverse abdominas strength training will be given 5 days a week and continued for 6 weeks.
Study: NCT05414214

Intervention type: PROCEDURE
Intervention: Thyromental Height Test
Description: Thyromental Height Test (TMHT) : will be measured while a patient is lying supine with the head and neck are maintained in a neutral position using a pillow under the head. By using a digital depth gauge, the TMH is the vertical distance measured between the anterior border of the thyroid cartilage directly on the thyroid notch and the anterior border of the mentum.

Intervention type: PROCEDURE
Intervention: Sternomental displacement
Description: Sternomental displacement (SMDD): While the patient is sitting with the head in a neutral position, SMD-neutral will be measured using a tape as the distance between upper borders of the manubrium sterni and the mentum. The SMD-extension will then be measured in the same way with the head extended on the neck. The difference between SMD-extension and SMD-neutral will then be calculated as SMDD.

Intervention type: PROCEDURE
Intervention: General anesthesia
Description: patients will be pre-oxygenated with 100% oxygen for 3 minutes, anesthesia will be then induced intravenously using fentanyl 2 μg/kg, propofol 1 -1.5 mg/kg, and succinylcholine 1 mg/kg lean body weight. Mask ventilation will be maintained till complete muscle relaxation guided by a peripheral nerve stimulator. Using Macintosh laryngoscopy, an anesthetist who has at least three years experience and who will be blinded to the preoperative tests' results, determined the best laryngeal view by using Cormack-Lehane (CL) grading system from I-IV. External neck manipulation will be used when needed to obtain the best laryngoscopic view. Endotracheal intubation will then be accomplished. The number and duration of intubation attempts will be recorded.
Study: NCT05951634

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PerQseal ELITE
Description: Percutaneous ELITE Arterial Closure Device~The term PerQseal Elite used singularly refers to the closure system comprising the closure device and Introducer. These individually are referred to as: PerQseal Elite VCD or PerQseal Elite closure device and/or PerQseal Elite Introducer.
Study: NCT05696067

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Corfluvec component 1 low dose
Description: Participants will receive single intranasal injection of H3N2 recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Corfluvec component 2 low dose
Description: Participants will receive single intranasal injection of H1N1pdm09 recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Corfluvec component 1 high dose
Description: Participants will receive single intranasal injection of H3N2 recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Corfluvec component 2 high dose
Description: Participants will receive single intranasal injection of H1N1pdm09 recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Corfluvec low dose
Description: Participants will receive two intranasal injections of recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2 tree weeks apart (H3N2 →H1N1pdm09)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Corfluvec high dose
Description: Participants will receive two intranasal injections of recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2 tree weeks apart (H3N2 →H1N1pdm09)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Corfluvec high dose
Description: Participants will receive two intranasal injections of recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2 tree weeks apart (H3N2 →H1N1pdm09)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive two intranasal injections of placebo three weeks apart

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive two intranasal injections of placebo three weeks apart
Study: NCT06424808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consolidating content on a single website and providing access to it via QR codes in a brochure format
Description: The group assigned to the experimental group will receive information in the same manner as current patients do, with the addition of receiving a brochure once when moving to a general ward after surgery. Afterward, they are free to use the brochure. The control group will receive information only in the manner currently provided to patients.
Study: NCT05423977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZV0203
Description: Participants will be allocated to one of the following dose groups: 0.3, 0.6, 1.2, 1.8, 2.7 and 3.6 mg/kg, and receive a treatment of ZV0203-ADC followed by 21 days of dose limited toxicity (DLT) observation period.
Study: NCT06032663

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET-MRI
Description: Patients that participate in the current study will have an extra PET-MRI scan, which will expose them to a small amount (4 - 6 mSv) of extra radiation.
Study: NCT06429865

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cytosponge
Description: Use of cytosponge as a tool to patients who need surveillance after endoscopic submucosal dissection for esophageal squamous cell carcinoma
Study: NCT06422039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7535（D）Tablets
Description: One HRS-7535（D）Tablet is administered to healthy subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7535（D）Tablets
Description: One HRS-7535（D）Tablet is administered to healthy subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7535（D）Tablets
Description: One HRS-7535（D）Tablet is administered to healthy subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7535（C）Tablets
Description: Two HRS-7535（C）Tablets is administered to healthy subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7535（C）Tablets
Description: Two HRS-7535（C）Tablets is administered to healthy subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7535（C）Tablets
Description: Two HRS-7535（C）Tablets is administered to healthy subjects.
Study: NCT06073288

Intervention type: OTHER
Intervention: Surgical specimens of CD and no-IBD patients
Description: Specimens of CD patients and patients without IBD-related disease (ex. diverticulitis) will be collected during the surgery, without other risks for the patients, since we will use only material left after pathologist analysis

Intervention type: OTHER
Intervention: Surgical specimens of CD and no-IBD patients
Description: Specimens of CD patients and patients without IBD-related disease (ex. diverticulitis) will be collected during the surgery, without other risks for the patients, since we will use only material left after pathologist analysis
Study: NCT06163118

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Deglut'G test
Description: Two tests to assess swallowing disorders using the Deglut'G tool will be carried out by a nurse or a caregiver from the Geriatric Short-Stay Unit, at visit 1.~The tests can be taken successively, or spaced apart by a time defined by the medical team, and will be taken blind to each other.~The average test administration time will be measured during the study, but the test should not exceed 10 minutes depending on the patients.~The Deglut'G tool consists of an initial administration of gelled water (1 to 3 teaspoons), to identify if a cough occurs. In the event of a cough, the oral treatment is stopped; if the cough is absent, a new step this time consists of the administration of water (1 to 3 sips). In case of cough, the food will be mixed, the liquids thickened, and the medicinal treatments crushed. If there is no cough, foods and liquids can be taken as normal.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SLP swallowing test
Description: At visit 1, 1 to 2 hours after the last Deglut'G test, a second swallowing test will be carried out by a SLP according to his skills and according to his usual practice, independently of the Deglut'G tool.~This test should not exceed 20-30 minutes depending on the patient.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ENT doctor swallowing test
Description: At Visit 2 (day 7 +/- 3 days after the inclusion), still as part of the short-stay hospitalization, the patient will meet an ENT doctor who will carry out an examination aimed at detecting swallowing disorders, according to his usual practice, of independent of the Deglut'G tool.~The examination should not exceed 20-30 minutes depending on the patient.
Study: NCT06007976

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia® Trident
Description: Low-level laser therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia® Trident
Description: Low-level laser therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia® Trident
Description: Low-level laser therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia® Trident
Description: Low-level laser therapy
Study: NCT05572203

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intrinsically labelled protein
Description: It is a protein drink that includes Intrinsically labelled Casein ( from Arla Foods), 13C/2H-labelled Spirulina (from CK Isotopes), and 13C/2H-labelled amino acids (from CK Isotopes)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intrinsically labelled protein
Description: It is a protein drink that includes Intrinsically labelled Casein ( from Arla Foods), 13C/2H-labelled Spirulina (from CK Isotopes), and 13C/2H-labelled amino acids (from CK Isotopes)
Study: NCT05033626

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simultaneous thyroidectomy and hyoid suspension
Description: Under endotracheal anesthesia, a horizontal skin incision up to 50 mm long is made at the level of the upper thyroid cartilage, the skin and subcutaneous fat are dissected. The sternohyoid and sternothyroid muscles are retracted. An audit of the thyroid gland is performed. Step by step, using the ultrasonic dissector, the sections of the gland necessary for resection are separated, ligated and transected. Using microsurgical techniques, neurolysis of the recurrent laryngeal nerves is performed. The quality control of the return of the laryngeal nerves is ensured to the required extent using the neuromonitoring apparatus.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thyroidectomy
Description: The hyoid bone is mobilized in the anterocaudal direction and is fixed to the thyroid cartilage with four permanent non-absorbable sutures. If sufficient mobilization does not occur during the operation, the tendon of the stylohyoid muscle is dissected. Surgical drainage is installed 24 hours after surgery.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Thyroidectomy
Description: The hyoid bone is mobilized in the anterocaudal direction and is fixed to the thyroid cartilage with four permanent non-absorbable sutures. If sufficient mobilization does not occur during the operation, the tendon of the stylohyoid muscle is dissected. Surgical drainage is installed 24 hours after surgery.
Study: NCT04745728

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 1mg/kg/d p.o.which will be tapered after 2 months and discontinued over a 6-12 month period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 1-2mg/kg/d p.o. with a target accumulated dose of 12g.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 1000mg I.V. on D1 and at 6 month. After 6 month, in patients with response but not complete remission, Rituximab could be stopped or repeated with a 6 month-interval (12 month, 18 month, 24 month) until complete remission. Rituximab 1000mg I.V. will be repeated on the 15th day of each Rituximab infusion if CD19+ B cell count\>5/ul.
Study: NCT05335616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guideline
Description: Hypothetical guideline regarding the indications and treatment steps involved in dental restoration repair.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment fee item
Description: Arrangement of a hypothetical treatment fee item which can be charged in addition to the actual repair restoration.